ENOVIS CORP (ENOV) Stock Fundamental Analysis

NYSE:ENOV • US1940141062

25.42 USD
+3.1 (+13.89%)
At close: Feb 26, 2026
25.42 USD
0 (0%)
After Hours: 2/26/2026, 5:28:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

ENOV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of ENOV while its profitability can be described as average. ENOV may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • ENOV had positive earnings in the past year.
  • ENOV had a positive operating cash flow in the past year.
  • In multiple years ENOV reported negative net income over the last 5 years.
  • Of the past 5 years ENOV 4 years had a positive operating cash flow.
ENOV Yearly Net Income VS EBIT VS OCF VS FCFENOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.84%, ENOV is in line with its industry, outperforming 42.70% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -67.66%, ENOV is in line with its industry, outperforming 45.41% of the companies in the same industry.
  • ENOV has a better Return On Invested Capital (0.12%) than 64.32% of its industry peers.
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROIC 0.12%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ENOV Yearly ROA, ROE, ROICENOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

  • Looking at the Operating Margin, with a value of 0.25%, ENOV is in the better half of the industry, outperforming 64.32% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ENOV has declined.
  • ENOV's Gross Margin of 57.19% is in line compared to the rest of the industry. ENOV outperforms 57.84% of its industry peers.
  • In the last couple of years the Gross Margin of ENOV has grown nicely.
Industry RankSector Rank
OM 0.25%
PM (TTM) N/A
GM 57.19%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
ENOV Yearly Profit, Operating, Gross MarginsENOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ENOV is destroying value.
  • ENOV has more shares outstanding than it did 1 year ago.
  • ENOV has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ENOV is higher compared to a year ago.
ENOV Yearly Shares OutstandingENOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENOV Yearly Total Debt VS Total AssetsENOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • ENOV has an Altman-Z score of 0.72. This is a bad value and indicates that ENOV is not financially healthy and even has some risk of bankruptcy.
  • ENOV has a Altman-Z score of 0.72. This is comparable to the rest of the industry: ENOV outperforms 49.19% of its industry peers.
  • ENOV has a debt to FCF ratio of 59.72. This is a negative value and a sign of low solvency as ENOV would need 59.72 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 59.72, ENOV is doing good in the industry, outperforming 67.03% of the companies in the same industry.
  • A Debt/Equity ratio of 0.66 indicates that ENOV is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.66, ENOV is doing worse than 65.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Altman-Z 0.72
ROIC/WACC0.01
WACC9.61%
ENOV Yearly LT Debt VS Equity VS FCFENOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

  • ENOV has a Current Ratio of 2.22. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
  • ENOV's Current ratio of 2.22 is in line compared to the rest of the industry. ENOV outperforms 43.24% of its industry peers.
  • A Quick Ratio of 1.16 indicates that ENOV should not have too much problems paying its short term obligations.
  • ENOV has a worse Quick ratio (1.16) than 70.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 1.16
ENOV Yearly Current Assets VS Current LiabilitesENOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 26.14% over the past year.
  • Measured over the past years, ENOV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.18% on average per year.
  • Looking at the last year, ENOV shows a quite strong growth in Revenue. The Revenue has grown by 11.57% in the last year.
  • ENOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.73% yearly.
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.19% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ENOV will show a quite strong growth in Revenue. The Revenue will grow by 8.87% on average per year.
EPS Next Y14.9%
EPS Next 2Y11.19%
EPS Next 3Y11.64%
EPS Next 5Y23.19%
Revenue Next Year7.32%
Revenue Next 2Y6%
Revenue Next 3Y6.02%
Revenue Next 5Y8.87%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENOV Yearly Revenue VS EstimatesENOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B
ENOV Yearly EPS VS EstimatesENOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 7.63 indicates a rather cheap valuation of ENOV.
  • Based on the Price/Earnings ratio, ENOV is valued cheaply inside the industry as 98.38% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.21, ENOV is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 7.27, the valuation of ENOV can be described as very cheap.
  • ENOV's Price/Forward Earnings ratio is rather cheap when compared to the industry. ENOV is cheaper than 98.38% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.13. ENOV is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 7.63
Fwd PE 7.27
ENOV Price Earnings VS Forward Price EarningsENOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 94.05% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ENOV indicates a somewhat cheap valuation: ENOV is cheaper than 71.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 63.86
EV/EBITDA 8.75
ENOV Per share dataENOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y11.19%
EPS Next 3Y11.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ENOV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENOVIS CORP

NYSE:ENOV (2/26/2026, 5:28:54 PM)

After market: 25.42 0 (0%)

25.42

+3.1 (+13.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners117.36%
Inst Owner Change0.03%
Ins Owners1.14%
Ins Owner Change0.32%
Market Cap1.45B
Revenue(TTM)2.23B
Net Income(TTM)-1.37B
Analysts84.44
Price Target46.36 (82.38%)
Short Float %15.5%
Short Ratio8.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.55%
Min EPS beat(2)7.76%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)8.22%
Min EPS beat(4)4.97%
Max EPS beat(4)13.35%
EPS beat(8)8
Avg EPS beat(8)7.21%
EPS beat(12)12
Avg EPS beat(12)8.15%
EPS beat(16)16
Avg EPS beat(16)8.66%
Revenue beat(2)0
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-0.21%
Max Revenue beat(2)-0.09%
Revenue beat(4)0
Avg Revenue beat(4)-0.8%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.09%
Revenue beat(8)2
Avg Revenue beat(8)-0.81%
Revenue beat(12)4
Avg Revenue beat(12)-0.8%
Revenue beat(16)5
Avg Revenue beat(16)-4.71%
PT rev (1m)0%
PT rev (3m)-9.09%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)1.06%
EPS NY rev (1m)0.29%
EPS NY rev (3m)2.05%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 7.63
Fwd PE 7.27
P/S 0.65
P/FCF 63.86
P/OCF 6.7
P/B 0.72
P/tB N/A
EV/EBITDA 8.75
EPS(TTM)3.33
EY13.1%
EPS(NY)3.5
Fwd EY13.76%
FCF(TTM)0.4
FCFY1.57%
OCF(TTM)3.8
OCFY14.93%
SpS39.05
BVpS35.33
TBVpS-8.37
PEG (NY)0.51
PEG (5Y)N/A
Graham Number51.45
Profitability
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.12%
ROICexgc 0.34%
OM 0.25%
PM (TTM) N/A
GM 57.19%
FCFM 1.02%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-45.54%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.8%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Debt/EBITDA 4.5
Cap/Depr 66.6%
Cap/Sales 8.7%
Interest Coverage 250
Cash Conversion 72.98%
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 1.16
Altman-Z 0.72
F-Score4
WACC9.61%
ROIC/WACC0.01
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
EPS Next Y14.9%
EPS Next 2Y11.19%
EPS Next 3Y11.64%
EPS Next 5Y23.19%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%
Revenue Next Year7.32%
Revenue Next 2Y6%
Revenue Next 3Y6.02%
Revenue Next 5Y8.87%
EBIT growth 1Y-35.24%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year76.65%
EBIT Next 3Y28.13%
EBIT Next 5Y28.11%
FCF growth 1Y122.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y609.06%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%

ENOVIS CORP / ENOV FAQ

What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ENOV.


What is the valuation status of ENOVIS CORP (ENOV) stock?

ChartMill assigns a valuation rating of 8 / 10 to ENOVIS CORP (ENOV). This can be considered as Undervalued.


Can you provide the profitability details for ENOVIS CORP?

ENOVIS CORP (ENOV) has a profitability rating of 4 / 10.


What is the earnings growth outlook for ENOVIS CORP?

The Earnings per Share (EPS) of ENOVIS CORP (ENOV) is expected to grow by 14.9% in the next year.